General Information of Drug Therapeutic Target (DTT) (ID: TTR5TV4)

DTT Name ERBB2 messenger RNA (HER2 mRNA)
Synonyms
Tyrosine kinase-type cell surface receptor HER2 (mRNA); Tyrosine kinase receptor ErbB2 (mRNA); Receptor tyrosine-protein kinase erbB-2 (mRNA); Proto-oncogene c-ErbB-2 (mRNA); Proto-oncogene Neu (mRNA); P185erbB2 (mRNA); NGL (mRNA); NEU proto-oncogene (mRNA); NEU (mRNA); Metastatic lymph node gene 19 protein (mRNA); MLN19 (mRNA); MLN 19 (mRNA); HER2/neu (mRNA); HER2 (erbB2/neu) (mRNA); HER-2 (mRNA); Erb2 (mRNA); Epidermal growth factor receptor 2 (mRNA); CD340 (mRNA); C-erbB-2 oncoprotein (mRNA); C-erbB-2 (mRNA)
Gene Name ERBB2
DTT Type
Clinical trial target
[1]
BioChemical Class
mRNA target
UniProt ID
ERBB2_HUMAN
TTD ID
T96788
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.10.1
Sequence
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
Function
Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.
KEGG Pathway
ErbB signaling pathway (hsa04012 )
Calcium signaling pathway (hsa04020 )
HIF-1 signaling pathway (hsa04066 )
Focal adhesion (hsa04510 )
Adherens junction (hsa04520 )
Pathways in cancer (hsa05200 )
Proteoglycans in cancer (hsa05205 )
MicroRNAs in cancer (hsa05206 )
Pancreatic cancer (hsa05212 )
Endometrial cancer (hsa05213 )
Prostate cancer (hsa05215 )
Bladder cancer (hsa05219 )
Non-small cell lung cancer (hsa05223 )
Central carbon metabolism in cancer (hsa05230 )
Reactome Pathway
PLCG1 events in ERBB2 signaling (R-HSA-1251932 )
PIP3 activates AKT signaling (R-HSA-1257604 )
GRB2 events in ERBB2 signaling (R-HSA-1963640 )
PI3K events in ERBB2 signaling (R-HSA-1963642 )
Constitutive Signaling by Aberrant PI3K in Cancer (R-HSA-2219530 )
Sema4D induced cell migration and growth-cone collapse (R-HSA-416572 )
RAF/MAP kinase cascade (R-HSA-5673001 )
SHC1 events in ERBB2 signaling (R-HSA-1250196 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
HKI-272 DM6QOVN Breast cancer 2C60-2C65 Phase 3 [1]
BMS-690514 DMX302C Chronic pain MG30 Phase 2 [2]
------------------------------------------------------------------------------------
26 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine DM0SCW9 Discovery agent N.A. Investigative [3]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [4]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [4]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [4]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [4]
4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole DMSXG23 Discovery agent N.A. Investigative [5]
4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole DMFEBCO Discovery agent N.A. Investigative [5]
4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole DMVN7GC Discovery agent N.A. Investigative [5]
4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole DMRGM21 Discovery agent N.A. Investigative [5]
4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide DMNE5H7 Discovery agent N.A. Investigative [6]
4557W DMLE0I7 Discovery agent N.A. Investigative [3]
AG-213 DMT3ML6 Discovery agent N.A. Investigative [7]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [8]
CL-387785 DMLKFZC Discovery agent N.A. Investigative [9]
Geldanamycin-estradiol hybrid DMUSJ96 Discovery agent N.A. Investigative [10]
HDS-029 DMLRUVA Discovery agent N.A. Investigative [9]
ISIS 12882 DMAXB8T Discovery agent N.A. Investigative [11]
ISIS 12883 DMND0JL Discovery agent N.A. Investigative [11]
ISIS 12884 DMS15A3 Discovery agent N.A. Investigative [11]
ISIS 9002 DMLIRKY Discovery agent N.A. Investigative [11]
ISIS 9003 DMBL2CG Discovery agent N.A. Investigative [11]
ISIS 9005 DM3PVGC Discovery agent N.A. Investigative [11]
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide DMEBGF1 Discovery agent N.A. Investigative [12]
PD-168393 DMN8M5P Discovery agent N.A. Investigative [12]
PMID24915291C38 DMBXT9J Discovery agent N.A. Investigative [13]
PNT-500 DMIEKVB Solid tumour/cancer 2A00-2F9Z Investigative [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Breast cancer 2C82 Breast tissue 3.50E-77 0.49 1.12
Rectal cancer 2C82 Rectal colon tissue 9.58E-01 -0.12 -0.23
Prostate cancer 2C82 Prostate 3.64E-01 -0.23 -0.38
Lung cancer 2C82 Lung tissue 7.14E-04 -0.13 -0.19
------------------------------------------------------------------------------------

References

1 Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
2 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
3 Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
4 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
5 Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8.
6 Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents. Bioorg Med Chem. 2010 Jan 15;18(2):880-6.
7 Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
8 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
9 Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
10 Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
11 US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression.
12 Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
13 Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).